"This study highlights the core underlying mechanism of action of our ovarian support cells in maturing eggs outside of the body and provides a deeper look into the role that Fertilo plays in promoting high quality egg maturation for IVF treatment," said Dr. Christian Kramme, Chief Scientific Officer of Gameto.
"These results demonstrate a marked change in how physicians will be able to diagnose and recommend treatment for prostate cancer patients," said Avenda Health CEO Shyam Natarajan, PhD. "By increasing the confidence in which we can predict a tumor's margins, patients and their doctors will have increased certainty that their entire tumor is treated and with the appropriate intervention in correlation to the severity of their case."
"This study highlights the core underlying mechanism of action of our ovarian support cells in maturing eggs outside of the body and provides a deeper look into the role that Fertilo plays in promoting high quality egg maturation for IVF treatment," said Dr. Christian Kramme, Chief Scientific Officer of Gameto.
The clinical study utilizing the STALIF C-Ti integrated cage-screw implants was performed in 145 patients and 12-month outcome scores demonstrated significant improvement in all available patient reported outcome scores collected (p<0.05 for all), including NDI, VAS neck, VAS left arm, and VAS right arm.
“This analysis provides the first clinical evidence that the Decipher Prostate classifier can help physicians and patients make critical, personalized treatment decisions in the post-biopsy, clinically high-risk prostate cancer setting,” said Elai Davicioni, Ph.D., Veracyte’s senior vice president of scientific and clinical operations, Urologic Cancers.
Study investigators performed complex modeling that also indicates the survival rate could be better with CyberKnife APBI than other radiation delivery approaches including volumetric-modulated arc therapy, three-dimensional conformal radiation therapy ABPI and high dose rate brachytherapy.
The Phase 2, U.S.-based, randomized, double-masked, multi-center, vehicle-controlled clinical trial of OTX-CSI was designed to evaluate safety, tolerability, durability, and efficacy of two different formulations of OTX-CSI by measuring signs and symptoms of DED in 140 subjects treated in both eyes over approximately 16 weeks (a 12-week study period, with an additional 4-week safety follow-up).
"These results are extremely encouraging. Glycemic control has been much harder to achieve in children due to unpredictable factors common in this age group, including physical growth and development, hormonal changes and active lifestyles.
The goal of Mayo Clinic’s COVID Virtual Recovery Study is to investigate the benefits of respiratory muscle training on strengthening the respiratory system and accelerating recovery from COVID-19.
